4.7 Article

Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006

Journal

DIABETOLOGIA
Volume 52, Issue 2, Pages 240-246

Publisher

SPRINGER
DOI: 10.1007/s00125-008-1204-8

Keywords

Breast cancer; Diabetes; Mortality; Mortality rate ratio; Secular trend

Funding

  1. New Century Health Care Promotion Foundation, the Department of Health [DOH89-TD1035, DOH97-TD-D-113-97009]
  2. National Taiwan University Hospital Yun-Lin Branch [NTUHYL96.G001]
  3. National Science Council of Taiwan [NSC-86-2314-B-002-326, NSC-872314-B-002-245, NSC88-2621-B-002-030, NSC89-2320-B002-125, NSC-90-2320-B-002-197, NSC-92-2320-B-002-156, NSC-93-2320-B-002-071, NSC-94-2314-B-002-142, NSC-95-2314-B-002-311, NSC-96-2314-B-002-061-MY2]

Ask authors/readers for more resources

Studies have identified an association between diabetes and breast cancer in postmenopausal women in Western countries. Such an association needs to be confirmed in an Asian population. The aim of this study was to evaluate the secular trend for breast cancer mortality in Taiwanese women in the general population and the mortality rate ratios between diabetic patients and the general population. Age-specific mortality rates for the general population, categorised into groups aged 25-54, 55-64, 65-74 and a parts per thousand yen75 years, were calculated for the years between 1995 and 2006 (inclusive) from vital statistics published by the Taiwanese government. Linear regression was used to test the trends. A total of 131,573 diabetic women aged a parts per thousand yen25 years from a national cohort recruited between 1995 and 1998 (inclusive) were followed prospectively for vital status, determined from the National Register of Deaths. Mortality rates and mortality rate ratios (mortality rate in diabetic women vs the average and highest mortality rates for the general population) were calculated. A total of 14,230 women aged a parts per thousand yen25 years in the general population died of breast cancer between 1995 and 2006. A trend for an increase in the annual rate was observed for all age groups. A total of 482 diabetic women died of breast cancer, with a crude mortality rate of 45.7 per 100,000 person-years. Compared with the general population the relative risk of mortality for those with diabetes ranged from 1.37 (for the group aged 55-64 years) to 2.43 (for the group aged 25-54 years). We identified a secular trend of an increase in the rate of breast cancer mortality in the Taiwanese general population. Our data suggest a higher risk of breast cancer mortality in diabetic patients in all age groups.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Metformin Use Is Associated with a Lower Risk of Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus

Chin-Hsiao Tseng

Summary: The risk of developing inflammatory bowel disease is lower in patients with type 2 diabetes mellitus who have been treated with metformin, compared to those who have never used it.

JOURNAL OF CROHNS & COLITIS (2021)

Article Endocrinology & Metabolism

Metformin use is associated with a lower risk of osteoporosis/vertebral fracture in Taiwanese patients with type 2 diabetes mellitus

Chin-Hsiao Tseng

Summary: The study found that the use of metformin is associated with a lower risk of osteoporosis and vertebral fractures. Both sexes in the patient population showed a dose-response pattern, with longer duration of metformin therapy consistently linked to reduced risk. The protective effect of metformin decreased with age but remained significant in patients aged 80 and older.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2021)

Article Biochemistry & Molecular Biology

Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus

Chin-Hsiao Tseng

Summary: This study investigated the association between metformin use and malignant brain tumors in patients with type 2 diabetes mellitus. The results showed a reduction in risk of malignant brain tumors associated with metformin use, especially after approximately 2-5 years of use.

BIOMOLECULES (2021)

Review Biochemistry & Molecular Biology

The Relationship between Diabetes Mellitus and Gastric Cancer and the Potential Benefits of Metformin: An Extensive Review of the Literature

Chin-Hsiao Tseng

Summary: Studies have shown a higher risk of gastric cancer in patients with diabetes mellitus, with those who have both conditions experiencing more complications and a poorer prognosis. However, glycemic control may improve in diabetes patients with gastric cancer following gastrectomy.

BIOMOLECULES (2021)

Article Respiratory System

Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study

Chin-Hsiao Tseng

Summary: A retrospective observational study in Taiwan found that the use of pioglitazone is associated with a significantly lower risk of developing COPD in patients with type 2 diabetes mellitus. No interactions between pioglitazone and COPD risk factors such as pneumonia, pulmonary tuberculosis, and tobacco abuse were noted.

INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2022)

Review Andrology

The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review

Chin-Hsiao Tseng

Summary: Metformin has various effects on men's health, with potential impacts on erectile dysfunction, steroidogenesis, spermatogenesis, prostate specific antigen, prostatitis, benign prostate hyperplasia, and prostate cancer. Studies on metformin's effects on these conditions are ongoing, with conflicting results on its effectiveness.

WORLD JOURNAL OF MENS HEALTH (2022)

Article Otorhinolaryngology

Metformin Reduces the Risk of Hearing Loss: A Retrospective Cohort Study

Chin-Hsiao Tseng

Summary: This retrospective cohort study investigated the association between metformin exposure and the risk of hearing loss. The results showed that patients with diabetes who used metformin had a lower risk of hearing loss. The risk reduction was more significant with longer duration of use and higher cumulative dose.

OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2023)

Article Oncology

The Risk of Multiple Myeloma Is Reduced in Metformin Initiators: A Retrospective Cohort Study in Taiwanese Patients with Type 2 Diabetes Mellitus

Chin-Hsiao Tseng

Summary: This study using Taiwan's National Health Insurance database found that type 2 diabetes patients who use metformin have a significantly lower risk of multiple myeloma, especially in patients who adhere to treatment.

CANCERS (2022)

Article Andrology

Pioglitazone and Prostate Cancer Risk in Taiwanese Male Patients with Type 2 Diabetes: A Retrospective Cohort Study

Chin-Hsiao Tseng

Summary: This study found an association between the use of pioglitazone and a lower risk of prostate cancer. Among patients using pioglitazone, a cumulative duration of therapy greater than 20.23 months or a cumulative dose greater than 15,330 mg was associated with a significantly reduced risk of prostate cancer, primarily in patients aged less than 65 years.

WORLD JOURNAL OF MENS HEALTH (2023)

Article Andrology

Effect of Metformin on Lower Urinary Tract Symptoms in Male Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study in Taiwan

Chin-Hsiao Tseng

Summary: This study examined the relationship between the use of metformin and the risk of lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH). The results showed that males with type 2 diabetes who used metformin had a significantly lower risk of LUTS/BPH.

WORLD JOURNAL OF MENS HEALTH (2023)

Article Chemistry, Medicinal

The Risk of Age-Related Macular Degeneration Is Reduced in Type 2 Diabetes Patients Who Use Metformin

Chin-Hsiao Tseng

Summary: This study confirms that metformin can reduce the risk of age-related macular degeneration (AMD) in patients with type 2 diabetes.

PHARMACEUTICALS (2023)

Article Chemistry, Medicinal

Pioglitazone Has a Null Association with Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus

Chin-Hsiao Tseng

Summary: This study investigated the potential effects of pioglitazone on inflammatory bowel disease (IBD). Using a nationwide database, the researchers found that pioglitazone did not have any significant impact on IBD risk in patients with type 2 diabetes mellitus.

PHARMACEUTICALS (2022)

Article Dermatology

Differential effects of metformin on immune-mediated and androgen-mediated non-cancer skin diseases in diabetes patients: a retrospective cohort study

Chin-hsiao Tseng

Summary: Metformin use is associated with a significantly lower risk of immune-mediated skin diseases but a lack of preventive effect on androgen-mediated skin diseases.

DERMATOLOGY (2023)

Article Chemistry, Medicinal

Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients

Chin-Hsiao Tseng

Summary: This study aimed to investigate the effect of rosiglitazone on the risk of inflammatory bowel disease (IBD). The results showed that rosiglitazone had no significant effect on the risk of IBD, but there might be a potential benefit on ulcerative colitis (UC).

PHARMACEUTICALS (2023)

Article Oncology

Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan

Chin-Hsiao Tseng

Summary: This study aims to investigate the association between TZD use and the risk of multiple myeloma. The findings suggest a lower risk of multiple myeloma associated with TZD, especially in patients aged 65 and above. TZD treatment may provide a survival advantage for patients.

CANCERS (2023)

No Data Available